Sorrento Therapeutics, Inc. Form SC 13D/A May 06, 2016 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

SCHEDULE 13D (Rule 13d-101)

#### (Amendment No. 2)

# INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a)

Sorrento Therapeutics, Inc. (Name of Issuer)

Common Stock, par value \$0.0001 per share (Title of Class of Securities)

83587F202 (CUSIP Number)

Leonard A. Potter

President and Managing Member

Wildcat Capital Management, LLC

888 Seventh Avenue

New York, NY 10106

(212) 468-5100 (Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

May 5, 2016

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

*Note.* Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

(Continued on following pages)

(Page 1 of 14 Pages)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (<u>"Act</u>") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, *see* the *Notes*).

# CUSIP No. 83587F202 13DPage 2 of 14 Pages

NAMES OF REPORTING PERSONS

1 <sup>r</sup>

Wildcat Capital Management, LLC CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

2

(see instructions)

(a)

(b) 3 SEC USE ONLY SOURCE OF FUNDS (see instructions)

4

OO (See Item 3) CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED

PURSUANT TO ITEM 2(d) or 2(e) CITIZENSHIP OR PLACE OF ORGANIZATION

SOLE

6

5

Delaware

		VOTING
	7	POWER
		-0-
		SHARED
NUMBER OF		VOTING
SHARES		POWER
	8	
BENEFICIALLY		2,499,936 (See
OWNED BY		Items 3, 4 and
EACH REPORTING		5)
	9	SOLE
PERSON WITH		DISPOSITIVE
		POWER

Edgar Filing: Sorrento	Therapeutics, I	nc Form SC 13D/A
------------------------	-----------------	------------------

	Edgar Filing: Sorrento Therapeutics, Inc Form SC 13D/A
	-0- 10 SHARED DISPOSITIVE POWER
	2,499,936 (See Items 3, 4 and 5)
	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
11	PERSON
12	2,499,936 (See Items 3, 4 and 5) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) PERCENT OF CLASS
13	REPRESENTED BY AMOUNT IN ROW 11
14	6.5% (See Item 5)* TYPE OF REPORTING PERSON
	00

The calculation assumes that there are a total of 38,365,767 shares of Common Stock (as defined herein) outstanding \* as of March 10, 2016, as set forth in the Issuer's Annual Report on Form 10-K for the fiscal year ended December 31, 2015, filed with the Securities and Exchange Commission (the <u>"SEC</u>") on March 15, 2016.

# CUSIP No. 83587F202 13DPage 3 of 14 Pages

NAMES OF REPORTING PERSONS

1

Wildcat – Liquid Alpha, LLC CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

2

(see instructions)

(a)

(b) 3 SEC USE ONLY SOURCE OF FUNDS (see instructions)

4

WC (See Item 3) CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED

PURSUANT TO ITEM 2(d) or 2(e) CITIZENSHIP OR PLACE OF ORGANIZATION

SOLE

6

5

Delaware

	7	VOTING POWER
		-0- Shared
NUMBER OF SHARES		VOTING POWER
	8	
BENEFICIALLY		184,000 (See
OWNED BY		Items 3, 4 and
EACH REPORTING		5)
PERSON WITH	9	SOLE DISPOSITIVE POWER

Edgar Filing: Sorrento	Thoropoution	Ino Form	
Lugar i ning. Somenio	merapeutics,	IIIC I UIII	130 13D/A

	Edgar Filing: Sorrento Therapeutics, Inc Form SC 13D/A
	-0- 10 SHARED DISPOSITIVE POWER
	184,000 (See Items 3, 4 and
11	5) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
11	184,000 (See Items 3, 4 and
	5) CHECK BOX IF
	THE AGGREGATE
12	AMOUNT IN ROW (11)
	EXCLUDES CERTAIN
	SHARES (see instructions)
	PERCENT OF CLASS REPRESENTED BY
13	AMOUNT IN ROW 11
	0.5% (See Item 5)* TYPE OF REPORTING
14	PERSON
	00

#### CUSIP No. 83587F202 13D Page 4 of 14 Pages

NAMES OF REPORTING PERSONS

1

Infinity Q Capital Management, LLC CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

# 2 (see instructions)

(a)

(b) 3 SEC USE ONLY SOURCE OF FUNDS (see instructions)

4 Instructions

OO (See Item 3) CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

- CITIZENSHIP OR PLACE OF ORGANIZATION
- 6

5

Delaware

	SOLE
	VOTING
7	POWER

		-0-
		SHARED
NUMBER OF		VOTING
SHARES		POWER
	8	
BENEFICIALLY		123,597 (See
OWNED BY		Items 3, 4 and
EACH REPORTING		5)

Edgar Filing: Sorrento Therapeutics, Inc. - Form SC 13D/A

PERSON WITH

- DISPOSITIVE
- 9 POWER

SOLE

-0-

10 SHARED DISPOSITIVE POWER

> 123,597 (See Items 3, 4 and 5)

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING

11 PERSON

12

14

123,597 (See Items 3, 4 and 5) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN

- SHARES (see instructions) PERCENT OF CLASS
- REPRESENTED BY13AMOUNT IN ROW 11

0.3% (See Item 5)\* TYPE OF REPORTING PERSON

00

#### CUSIP No. 83587F202 13D Page 5 of 14 Pages

NAMES OF REPORTING PERSONS

1

Infinity Q Management Equity, LLC CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

2

<sup>2</sup> (see instructions)

(a)

(b) 3 SEC USE ONLY SOURCE OF FUNDS (see instructions)

4 instructions

OO (See Item 3) CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

ORGANIZATION

CITIZENSHIP OR PLACE OF

6

5

Delaware

	SOLE
	VOTING
7	POWER

		-0-
		SHARED
NUMBER OF		VOTING
SHARES		POWER
	8	
BENEFICIALLY		123,597 (See
OWNED BY		Items 3, 4 and
EACH REPORTING		5)

Edgar Filing: Sorrento Therapeutics, Inc. - Form SC 13D/A

PERSON WITH

- DISPOSITIVE
- 9 POWER

SOLE

-0-

10 SHARED DISPOSITIVE POWER

> 123,597 (See Items 3, 4 and 5)

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING

11 PERSON

12

14

123,597 (See Items 3, 4 and 5) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see

- instructions) PERCENT OF CLASS REPRESENTED BY
- 13 AMOUNT IN ROW 11

0.3% (See Item 5)\* TYPE OF REPORTING PERSON

00

#### CUSIP No. 83587F202 13DPage 6 of 14 Pages

NAMES OF REPORTING PERSONS

1

Infinity Q Diversified Alpha Fund CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

2 (see instructions)

(a)

(b)

3 SEC USE ONLY SOURCE OF FUNDS (see instructions)

4

WC (See Item 3) CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) CITIZENSHIP OR PLACE OF

6

5

Delaware

ORGANIZATION

		VOTING
	7	POWER
		-0-
		SHARED
NUMBER OF		VOTING
SHARES		POWER
	8	
BENEFICIALLY		123,597 (See
OWNED BY		Items 3, 4 and
EACH REPORTING		5)
	9	

SOLE

PERSON WITH		SOLE DISPOSITIVE POWER	
	10	-0- SHARED DISPOSITIVE POWER	
		123,597 (See Items 3, 4 and 5)	
		FE AMOUNT	
	BENEFICIALLY OWNED BY EACH REPORTING		
11	PERSON		
12	123,597 (See 5) CHECK BO THE AGGREGA AMOUNT II ROW (11) EXCLUDES CERTAIN SHARES (see	ΓE N	
	instructions)		
	PERCENT C		
13	REPRESEN' AMOUNT I		
15			
14	0.3% (See Ite TYPE OF RI PERSON	,	
	00		

# CUSIP No. 83587F202 13DPage 7 of 14 Pages

NAMES OF REPORTING PERSONS

1

Bonderman Family Limited Partnership CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

2 (see instructions)

(a)

(b)

3 SEC USE ONLY SOURCE OF FUNDS (see

4 instructions)

Texas

WC (See Item 3) CHECK IF DISCLOSURE OF LEGAL

5 PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) CITIZENSHIP OR PLACE OF ORGANIZATION

6

1 Undo		
		SOLE
		VOTING
	7	POWER
		-0-
		SHARED
NUMBER OF		VOTING
SHARES		POWER
	8	
BENEFICIALLY		2,623,533 (See
OWNED BY		Items 3, 4 and
EACH REPORTING		5)
	9	SOLE
PERSON WITH		DISPOSITIVE

Edgar Filing: Sorrento Therapeutics, Inc. - Form SC 13D/A

POWER

-0-10 SHARED DISPOSITIVE POWER 2,623,533 (See Items 3, 4 and 5) AGGREGATE AMOUNT **BENEFICIALLY OWNED** BY EACH REPORTING PERSON 2,623,533 (See Items 3, 4 and 5) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) **EXCLUDES** CERTAIN SHARES (see instructions)

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

> 6.8% (See Item 5)\* TYPE OF REPORTING PERSON

11

12

13

14

PN

# CUSIP No. 83587F202 13D Page 8 of 14 Pages

NAMES OF REPORTING PERSONS

1

Leonard A. Potter CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

2

(see instructions)

(a)

(b) 3 SEC USE ONLY SOURCE OF FUNDS (see instructions)

4

OO (See Item 3) CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED

PURSUANT TO ITEM 2(d) or 2(e) CITIZENSHIP OR PLACE OF ORGANIZATION

> SOLE VOTING

6

5

United States

	7	POWER
NUMBER OF		-0- SHARED VOTING
SHARES		POWER
	8	
BENEFICIALLY		2,623,533 (See
OWNED BY		Items 3, 4 and
EACH REPORTING		5)
	9	SOLE
PERSON WITH		DISPOSITIVE
		POWER

Edgar Filing: Sorrento	Therapeutics, I	nc Form SC 13D/A
------------------------	-----------------	------------------

	Lugar Filling. Soffento Therapeutics, inc Form SO 15D/A
	-0- 10 SHARED DISPOSITIVE POWER
	2,623,533 (See Items 3, 4 and 5)
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
11	PERSON
	2,623,533 (See Items 3, 4 and 5) CHECK BOX IF THE
	AGGREGATE
12	AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) PERCENT OF CLASS
12	REPRESENTED BY
13	AMOUNT IN ROW 11
14	6.8% (See Item 5)* TYPE OF REPORTING PERSON
	IN

#### CUSIP No. 83587F202 13DPage 9 of 14 Pages

NAMES OF REPORTING PERSONS

1

James Velissaris CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

2 (see instructions)

(a)

(b)

3 SEC USE ONLY SOURCE OF FUNDS (see instructions)

4

OO (See Item 3) CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) CITIZENSHIP OR PLACE OF

6

5

United States

NUMBER OF SHARES

ORGANIZATION

	SOLE
	VOTING
7	POWER
	-0-
	SHARED
	VOTING
	POWER
8	
	123,597 (See

BENEFICIALLY123,597 (SeeOWNED BYItems 3, 4 andEACH REPORTING5)

PERSON WITH		SOLE DISPOSITIVE POWER	
		10	-0- SHARED DISPOSITIVE POWER
			123,597 (See Items 3, 4 and 5)
			E AMOUNT LLY OWNED
			EPORTING
11	PERSON		
11	I LIGOI	•	
	123,597	(See	Items 3, 4 and
	5)	(	,
	CHECK	BO	X IF
	THE		
	AGGRE	GAT	Έ
	AMOUN	IT II	N
12	<b>ROW</b> (1	1)	
	EXCLUI		
	CERTAI		
	SHARES		e
	instructio		
			OF CLASS
13	REPRES		NROW 11
15	AWOUN	11 11	
	0.3% (Se	e Ite	em 5)*
	TYPE OF REPORTING		
14	PERSON		
14	IN		
	11.N		

This Amendment No. 2 (the <u>"Amendment</u>") amends and supplements the Schedule 13D filed on April 18, 2016, as amended and supplemented by Amendment No. 1 filed on April 26, 2016 (as so amended, the <u>"Original Schedule 13D</u>" and, as further amended and supplemented by this Amendment, the <u>"Schedule 13D</u>") by Wildcat Capital Management, LLC, Wildcat – Liquid Alpha, LLC, Infinity Q Capital Management, LLC, Infinity Q Management Equity, LLC, Infinity Q Diversified Alpha Fund, Bonderman Family Limited Partnership, Leonard A. Potter and James Velissaris with respect to the Common Stock of the Issuer. Capitalized terms used in this Amendment and not otherwise defined shall have the same meanings ascribed to them in the Original Schedule 13D.

# Item 4. Purpose of Transaction

This Amendment amends and restates the fourth paragraph of Item 4 of the Original Schedule 13D in its entirety as set forth below:

"Accordingly, on April 25, 2016, WLA filed a verified complaint for the inspection of books and records (the "Complaint") in the Court of Chancery of the State of Delaware seeking an order compelling the Issuer to provide WLA certain books and records of the Issuer for inspection and copying pursuant to Section 220 of the Delaware General Corporation Law. A copy of the Complaint is attached as Exhibit 3.

On May 5, 2016, WLA and BFLP submitted a letter (the "May 5 Letter") to the Issuer's board of directors (the "Board") reiterating certain concerns regarding the Transactions and additionally setting forth their belief that (i) the Issuer's Chief Executive Officer ("CEO"), Dr. Henry Ji, has consistently acted in a manner that is not in the best interests of the Issuer's shareholders and has destroyed significant shareholder value and (ii) the Board has failed to act in the best interests of the Issuer's shareholders and has breached its fiduciary duties owed to such shareholders. Accordingly, WLA and BLFP set forth certain demands in the May 5 Letter, including that the Board: (i) immediately terminate Dr. Ji as the CEO; (ii) immediately terminate the Transactions that have not already closed to avoid further dilution to the existing shareholders; (iii) appoint three directors to be nominated by WLA and BFLP to lead a special committee of the Board (the "Special Committee") to undertake the actions necessary to preserve and maximize shareholder value; (iv) authorize the Special Committee to seek and appoint an interim CEO and, if necessary, a permanent replacement for Dr. Ji with more commercial and executive experience; (v) authorize the Special Committee to engage an investment banker to initiate a sale process for the entire company; (vi) in the event that there are no buyers for the entire company, authorize the Special Committee to sell selected non-strategic assets of the Issuer, including its minority investments in private companies, and unwind its minority positions in joint ventures so that it can focus on, maintain control of, and finance the development of the Issuer's remaining assets; and (vii) in the event that neither the Issuer nor selected assets can be sold, management and the Special Committee should develop a well-defined and financed business plan that maximizes the value of the Issuer's existing assets and further, the Issuer should immediately stop any further financial engineering efforts and under no circumstances should the Issuer acquire any additional assets for development. The May 5 Letter also provided that if the Board refuses to meet WLA's and BFLP's demands, the Board should immediately resign and allow another slate of directors to take the actions that are required to protect and maximize shareholder value. Further, to address certain concerns regarding option and warrant grants, WLA and BFLA intend to pursue their available remedies including, among other things, legal action on the Issuer's behalf. A copy of the May 5 Letter is attached as Exhibit 4.

Wildcat has raised, or may further raise, its concerns regarding the Transactions, management of the Issuer, the Board and related matters with management or directors of the Issuer, other shareholders and regulators."

#### Item 7. Material to Be Filed as Exhibits

1.

This Amendment amends and restates Item 7 of the Original Schedule 13D in its entirety as set forth below:

- Agreement of Joint Filing as required by Rule 13d-1(k)(1) under the Act. 2.
  - Demand for Inspection of Books and Records, dated April 11, 2016.

Page 10 of 14

3. Verified Complaint for Inspection of Books and Records filed in the Court of Chancery of the State of Delaware on April 25, 2016.

4. Letter to the Board of Directors of the Issuer, dated May 5, 2016.

Page 11 of 14

#### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: May 6, 2016

Wildcat Capital Management, LLC

By: <u>/s/ Leonard A. Potter</u> Name: Leonard A. Potter Title: President

Wildcat - Liquid Alpha, LLC

By: <u>/s/ Clive Bode</u> Name: Clive Bode Title: President

Infinity Q Capital Management, LLC

By: <u>/s/ Leonard A. Potter</u> Name: Leonard A. Potter Title: Chief Executive Officer

Infinity Q Management Equity, LLC

By: <u>/s/ James Velissaris</u> Name: James Velissaris Title: Sole Manager

Infinity Q Diversified Alpha Fund

By: Infinity Q Capital Management, LLC

By: <u>/s/ Leonard A. Potter</u> Name: Leonard A. Potter Title: Chief Executive Officer Page 12 of 14

Bonderman Family Limited Partnership

By: <u>/s/ Clive Bode</u> Name: Clive Bode Title: President

Leonard A. Potter

By: <u>/s/ Leonard A. Potter</u> Name: Leonard A. Potter

James Velissaris

By: <u>/s/ James Velissaris</u> Name: James Velissaris

Page 13 of 14

# Edgar Filing: Sorrento Therapeutics, Inc. - Form SC 13D/A

#### INDEX TO EXHIBITS

Agreement of Joint Filing as required by Rule 13d-1(k)(1) under the Act.\*

Demand for Inspection of Books and Records, dated April 11, 2016.\*\*

Verified Complaint for Inspection of Books and Records filed in the Court of Chancery of the State of Delaware on 3. A will 25, 2016 that April 25, 2016.\*\*\*

4.

1.

2.

Letter to the Board of Directors of the Issuer, dated May 5, 2016.

\*\*Incorporated herein by reference to Demand for Inspection of Books and Records, dated April 11, 2016, which was previously filed with the SEC as Exhibit 2 to Schedule 13D filed by Wildcat Capital Management, LLC, Wildcat – Liquid Alpha, LLC, Infinity Q Capital Management, LLC, Infinity Q Management Equity, LLC, Infinity Q Diversified Alpha Fund, Bonderman Family Limited Partnership, Leonard A. Potter and James Velissaris, on April 18, 2016.

\*\*\*Incorporated herein by reference to Verified Complaint for Inspection of Books and Records filed in the Court of Chancery of the State of Delaware on April 25, 2016, which was previously filed with the SEC as Exhibit 3 to Amendment No. 1 to Schedule 13D filed by Wildcat Capital Management, LLC, Wildcat – Liquid Alpha, LLC, Infinity Q Capital Management, LLC, Infinity Q Management Equity, LLC, Infinity Q Diversified Alpha Fund, Bonderman Family Limited Partnership, Leonard A. Potter and James Velissaris, on April 26, 2016.

Page 14 of 14

<sup>\*</sup>Incorporated herein by reference to the Agreement of Joint Filing by and among Wildcat Capital Management, LLC, Wildcat - Liquid Alpha, LLC, Infinity O Capital Management, LLC, Infinity O Management Equity, LLC, Infinity O Diversified Alpha Fund, Bonderman Family Limited Partnership, Leonard A. Potter and James Velissaris, dated as of April 18, 2016, which was previously filed with the SEC as Exhibit 1 to Schedule 13G filed by Wildcat Capital Management, LLC, Wildcat - Liquid Alpha, LLC, Infinity Q Capital Management, LLC, Infinity Q Management Equity, LLC, Infinity Q Diversified Alpha Fund, Bonderman Family Limited Partnership, Leonard A. Potter and James Velissaris, on April 18, 2016.